Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
NBRV was delisted on the 31st of July, 2023.
42 hedge funds and large institutions have $73.3M invested in Nabriva Therapeutics plc Ordinary Shares Ireland in 2018 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 15 increasing their positions, 10 reducing their positions, and 11 closing their positions.
307% more call options, than puts
Call options by funds: $492K | Put options by funds: $121K
50% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 10
9% less funds holding
Funds holding: 46 → 42 (-4)
36% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 11
42% less capital invested
Capital invested by funds: $127M → $73.3M (-$53.9M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.06M |
| 2 |
PM
Prosight Management
Dallas,
Texas
|
+$819K |
| 3 |
WS
Wedbush Securities
Los Angeles,
California
|
+$488K |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$294K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$249K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VP
venBio Partners
San Francisco,
California
|
-$8.91M |
| 2 |
Millennium Management
New York
|
-$4.14M |
| 3 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$2.81M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$2.63M |
| 5 |
MWNA
Marshall Wace North America
New York
|
-$1.9M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
JP Morgan Chase
New York
| – | -$126K | -100 | Closed |
|
|
ARTA
52
A.R.T. Advisors
New York
| – | -$61K | -49 | Closed |
|
53
Citigroup
New York
| – | -$1K | -1 | Closed |
|
NBRV Hedge Fund Activity: Q2 2018 in Review
42 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) for Q2 2018, worth a combined $73.3M — down 42% from $127M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of NBRV and 7 opened new positions — a net loss of 4 holders — while 10 trimmed existing stakes and 15 added.
The largest buyer was Dimensional Fund Advisors, adding an estimated $1.06M. The largest seller was venBio Partners, cutting an estimated $8.91M.
- 42 institutional investors held Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) as of Q2 2018, down from 46 in Q1 2018.
- Funds reported $73.3M of Nabriva Therapeutics plc Ordinary Shares Ireland stock for Q2 2018, down 42% quarter-over-quarter.
- 7 funds opened new Nabriva Therapeutics plc Ordinary Shares Ireland positions in Q2 2018 and 11 closed out, a net change of -4 holders.
- The largest Nabriva Therapeutics plc Ordinary Shares Ireland buyer in Q2 2018 was Dimensional Fund Advisors, an estimated $1.06M added.
- The largest Nabriva Therapeutics plc Ordinary Shares Ireland seller in Q2 2018 was venBio Partners, an estimated $8.91M sold.
Based on aggregated 13F filings for Q2 2018.